Drug manufacturer, Matrix Laboratories has informed that US Food and Drug Administration (USFDA) has given tentative nod to market Lamivudine tablets (300 mg) and Tenofovir disoproxil fumarate tablets (300 mg).

The source close to the company said that Lamivudine is recommended for treatment of chronic hepatitis B at a lower dose than for treatment of HIV.

While Tenofovir disoproxil fumarate tablets are suggested in combination with other antiretroviral agents in the treatment of HIV infections in grownups.

Stock of Pharmaceuticals major Matrix Laboratories ended well in an unpredictable market session at Rs 137, up 1 percent on National Stock Exchange. The total volume of shares traded at the NSE was 16,370.